NCT03628365View on ClinicalTrials.gov

Can Beta-Hydroxy-beta-Methylbutyrate Supplementation Counteract Muscle Catabolism in Critically Ill Patients?

NACompletedINTERVENTIONAL
Enrollment

37

Participants

Timeline

Start Date

September 17, 2018

Primary Completion Date

January 6, 2020

Study Completion Date

January 6, 2020

Conditions
Critical IllnessMuscle Weakness
Interventions
DIETARY_SUPPLEMENT

HMB (beta-hydroxy beta-methylbutyrate)

1.5 g, b.i.d., by the enteral route, from Day 4 to Day 30 (minimum 10 days)

Trial Locations (1)

1011

University of Lausanne Hospitals, Lausanne

All Listed Sponsors
collaborator

Texas A&M University

OTHER

lead

Mette M Berger

OTHER

NCT03628365 - Can Beta-Hydroxy-beta-Methylbutyrate Supplementation Counteract Muscle Catabolism in Critically Ill Patients? | Biotech Hunter | Biotech Hunter